Control Dominating Subclones for Managing Cancer Progression and ...
online.liebertpub.com/doi/abs/10.1089/scd.2011.0267
by SC Li - 2011 - Cited by 13 - Related articles
Nov 2, 2011 - ... Managing Cancer Progression and Posttreatment Recurrence by Subclonal Switchboard Signal: Implication for New Therapies. To cite this article: Shengwen Calvin Li, Katherine L. Lee, and Jane Luo. Stem Cells and Development. September 2011, 21(4): 503-506. https://doi.org/10.1089/scd.2011.0267.
Control Dominating Subclones for Managing Cancer Progression and Posttreatment Recurrence by Subclonal Switchboard Signal: Implication for New Therapies
To cite this article:Shengwen Calvin Li, Katherine L. Lee, and Jane Luo. Stem Cells and Development. September 2011, 21(4): 503-506. https://doi.org/10.1089/scd.2011.0267
Online Ahead of Print: November 2, 2011
Online Ahead of Editing: September 20, 2011
Published in Volume: 21 Issue 4: September 20, 2011
http://online.liebertpub.com/doi/abs/10.1089/scd.2011.0267
- Full Text HTML
- Full Text PDF (167.9 KB)
- Full Text PDF with Links (218.4 KB)
Author information
Shengwen Calvin Li, 1 Katherine L. Lee, 1 and Jane Luo2
1Neuro-Oncology and Stem Cell Research Laboratory, CHOC Children's Hospital Research Institute, University of California Irvine, Orange, California.
2Beckman Coulter, Inc., Brea, California.
Received for publication May 26, 2011
Accepted after revision September 20, 2011
Accepted after revision September 20, 2011
ABSTRACT
In contrast to hematological malignancies, meaningful improvements in survival statistics for patients with malignant brain tumors have not been realized in >40 years of clinical research. Clearly, a new medical approach to brain cancers is needed. Recent research has led to a new concept that needs to destroy all cancer subclones to control the cancer progression. However, this new concept fails to distinguish the difference between dominating subclones and dormant subclones. Here, we address the issue of clonal switch and emphasize that there may be one or more than one dominant clones within the tumor mass at any time. Destructing one dominant clone triggers activating other dormant subclones to become dominating subclones, causing cancer progress and post-treatment cancer recurrence. We postulate the concept of subclonal switchboard signaling and the pathway that involved in this process. In the context of stem cell and development, there is a parallel with the concept of quiescent/dormant cancer stem cells (CSC) and their progeny, the differentiated cancer cells; these 2 populations communicate and co-exist. The mechanism with which determines to extend self-renewal and expansion of CSC is needed to elucidate. We suggest eliminating the “dominating subclonal switchboard signals” that shift the dormant subclones to dominating subclones as a new strategy.
This paper was cited by:
Current achievements and future perspectives of metronomic chemotherapy
Adriana RomitiMetronomic Chemotherapy: Direct Targeting of Cancer Cells after all?
Nicolas AndréWhole genome sequencing discriminates hepatocellular carcinoma with intrahepatic metastasis from multi-centric tumors
Mayuko FurutaThe priming induction regimen of HAG as a low dose chemotherapy strategy in AML clonal evolution
AiLi ChenTissue Elasticity Regulated Tumor Gene Expression: Implication for Diagnostic Biomarkers of Primitive Neuroectodermal Tumor
Long T. VuCancer genomic research at the crossroads: realizing the changing genetic landscape as intratumoral spatial and temporal heterogeneity becomes a confounding factor
Shengwen Calvin LiCancer stem cells from a rare form of glioblastoma multiforme involving the neurogenic ventricular wall
Shengwen Li